Gelteq Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Public

  • Employees
  • 8

Employees

  • Stock Symbol
  • GELS

Stock Symbol

  • Share Price
  • $0.40
  • (As of Friday Closing)

Gelteq General Information

Description

Gelteq Ltd is a clinical and science-based company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products, preserving the simplicity, accessibility, and efficacy of oral delivery. Its principal products are edible gels and their application in gel-based dosage forms across pets, sports, pharmaceutical, over-the-counter, and nutraceutical categories, leveraging its patent pending multiple ingredient dosage forms. The company develops and tests gel-based delivery systems for humans and pets and focuses on out-licensing its technology to companies to create products that can be manufactured and sold, while continuing to manufacture existing products under license on a white label basis.

Contact Information

Website
www.gelteq.com
Formerly Known As
Gelteq Pty Ltd., Myhypo Pty Ltd
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • Monash Innovation Labs
  • G.60, 22 Alliance Lane
  • Clayton, Victoria 3800
  • Australia
+61 (03)
Primary Industry
Drug Delivery
Stock Exchange
NAS
Vertical(s)
Manufacturing, Life Sciences
Corporate Office
  • Monash Innovation Labs
  • G.60, 22 Alliance Lane
  • Clayton, Victoria 3800
  • Australia
+61 (03)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Gelteq Stock Performance

As of 13-Nov-2026, Gelteq’s stock price is $0.40. Its current market cap is $4.07M with 10.7M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.40 $0.38 $0.38 - $2.01 $4.07M 10.7M 2.81M -$0.44

Gelteq Financials Summary

As of 31-Dec-2025, Gelteq has a trailing 12-month revenue of $107K.

In Thousands,
USD 		TTM 31-Dec-2025 FY 2025 30-Jun-2025 FY 2024 30-Jun-2024 FY 2023 30-Jun-2023
EV 11,098 17,225
Revenue 107 107 0 54
EBITDA (2,365) (2,283) (1,146) (1,261)
Net Income (4,564) (4,300) (2,324) (2,357)
Total Assets 13,472 14,027 13,875 14,890
Total Debt 3,423 2,755 2,569 1,647
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Gelteq Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Gelteq‘s full profile, request access.

Request a free trial

Gelteq Patents

  • 44

    Total Documents Applications and Grants

  • Total Patents Families

  • 14

    Granted

  • 26

    Pending

  • Expiring in next 12 mo

Gelteq Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2026907642-A0 Pill crushing device & method Pending 08-Sep-2026
GB-202417250-D0 Pharmaceutical formulations Pending 25-Nov-2024
GB-202417258-D0 Pharmaceutical formulations Pending 25-Nov-2024
GB-202417264-D0 Pharmaceutical formulations Pending 25-Nov-2024
GB-2702651-A Pharmaceutical formulations Pending 25-Nov-2024 A61K9/0095
To view Gelteq’s complete patent history, request access »

Gelteq Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Gelteq Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Gelteq‘s full profile, request access.

Request a free trial

Gelteq ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Gelteq’s complete esg history, request access »

Gelteq FAQs

  • When was Gelteq founded?

    Gelteq was founded in 2008.

  • Where is Gelteq headquartered?

    Gelteq is headquartered in Clayton, Australia.

  • What is the size of Gelteq?

    Gelteq has 8 total employees.

  • What industry is Gelteq in?

    Gelteq’s primary industry is Drug Delivery.

  • Is Gelteq a private or public company?

    Gelteq is a Public company.

  • What is Gelteq’s stock symbol?

    The ticker symbol for Gelteq is GELS.

  • What is the current stock price of Gelteq?

    As of 13-Nov-2026 the stock price of Gelteq is $0.40.

  • What is the current market cap of Gelteq?

    The current market capitalization of Gelteq is $4.07M.

  • What is Gelteq’s current revenue?

    The trailing twelve month revenue for Gelteq is $107K.

  • What is Gelteq’s annual earnings per share (EPS)?

    Gelteq’s EPS for 12 months was -$0.44.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process